No objective cancer regression was observed, however a dose limiting toxicity (DLT) was not reached in this study due to the development of neutralizing antibodies against the recombinant cytokine.
Non se observou unha regresión obxectiva do cancro, porén neste estudo non se chegou a unha toxicidade limitante de dose (DLT) ao desenvolvemento de anticorpos neutralizantes contra a citocina recombinante.